Loading
Life sciences · Journal article
Frontiers in Oncology · November 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Purpose To evaluate the impact of initial recurrence and metastatic sites on survival outcomes in gastric cancer patients after radical gastrectomy. Methods A retrospective study was conducted on 1,140 patients with pathologically confirmed gastric cancer who underwent radical gastrectomy between September 2016 and December 2023. Patients were categorized into six groups according to initial recurrence and recurrence site: no recurrence, local recurrence, liver metastasis, peritoneal/retroperitoneal metastasis, multiple-site peritoneal metastasis, and other sites. Overall survival (OS) and Post-Recurrence Survival (PRS) were analyzed using Kaplan–Meier and log-ran k tests. Independent prognostic factors were identified by Cox regression. Results Age ≥60 years, CEA ≥5U/ml, pathological type (other), T4 Stage, perineural invasion and lymphovascular invasion were independent risk factors for poor OS, while middle-third and lower-third gastric location were protective factors. As for DFS, tumor differentiation, lymph node metastasis, perineural invasion, and site of recurrence/metastasis were significantly associated with the PRS. In the multivariable analysis, only perineural invasion remained an independent risk factor for PRS ( HR = 1.588, P = 0.005). Among 222 patients with recurrence, patients with Multiple-site peritoneal metastasis had the numerically shortest median OS (20 months, 95% CI 17.040–22.960) among the five recurrence subgroups. No statistically significant between-group differences were identified after Bonferroni correction for 10 pairwise log-rank comparisons. PRS was longest in liver metastasis patients (10 months), significantly longer than multiple-site peritoneal metastasis (3 months, P < 0.001), and patients with peritoneal/retroperitoneal metastasis had longer PRS than those with multiple-site peritoneal metastases (5 vs. 3 months, P = 0.028). Comprehensive therapy was associated with significantly longer PRS compared with supportive care (9 vs. 3 months, P < 0.001) and chemotherapy alone (9 vs. 4 months, P = 0.002). Conclusion PRS differed among patients with different initial recurrence/metastatic patterns. However, the initial recurrence/metastatic site was not independently associated with PRS. Perineural invasion was independently associated with shorter PRS and OS and may serve as a reference factor for post-recurrence prognostic assessment. Patients receiving comprehensive therapy after recurrence showed longer PRS.